Werewolf Therapeutics Reports First Quarter 2021 Finances

Werewolf Therapeutics Reports First Quarter 2021 Finances

Cautionary Note Regarding Forward-Looking Statements Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. This press release contains forward-looking statements that involve substantial risk and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf’s strategy, future operations, prospects, plans, objectives of management, the expected timeline for submitting investigational new drug applications and its sufficiency of its cash resources constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies; the timing of and our ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; the Company’s ability to obtain sufficient cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; the impact of the COVID-19 pandemic on the Company’s business and operations; as well as the risks and uncertainties identified in the “Risk Factors” section of the Company’s final prospectus dated April 29, 2021 for its initial public offering filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, with the Securities and Exchange Commission (“SEC”) and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Cash position: As of March 31, 2021, cash and cash equivalents decreased to $84.6 million, compared to $92.6 million as of December 31, 2020. The Company expects that its existing cash and cash equivalents, together with the net proceeds from the IPO, will be sufficient to fund its operations for at least the next twenty-four months.Research and development expenses: Research and development expenses were $4.8 million for the first quarter of 2021, compared to $2.8 million for the same period in 2020. The increase in research and development expenses was primarily due to manufacturing expenses incurred to support the production of preclinical and future clinical trial materials associated with the Company’s product candidates WTX-124, WTX-330 and WTX-613 and increased employee compensation costs related to increased headcount.General and administrative expenses: General and administrative expenses were $2.6 million for the first quarter of 2021, compared to $1.1 million for the same period in 2020. The increase in general and administrative expenses was primarily due to increased personnel, consulting and recruiting costs in preparation for increased requirements of operating as a public company.Net loss: Net loss was $7.4 million for the first quarter of 2021, compared to $3.8 million for the same period in 2020. First Quarter 2021 Financial Highlights

About Werewolf Therapeutics: Successful Initial Public Offering Completed: On May 4, 2021, Werewolf completed its initial public offering (IPO). In connection with the offering, the Company issued and sold 7,500,000 shares of common stock at a public offering price of $16.00 per share, resulting in net proceeds of approximately $108.9 million.

 March 31, 2021December 31, 2020Cash and cash equivalents$84,602 $92,570 Working capital$79,456 $87,630 Total assets$89,436 $96,398 Total stockholders’ deficit$(153,754)$(51,863) Investor Contact: Werewolf Therapeutics, Inc.Selected Condensed Consolidated Balance Sheet Data (unaudited)(amounts in thousands)

 Three Months EndedMarch 31,  2021   2020  Operating expenses:      Research and development$4,817  $2,763  General and administrative 2,635   1,131  Total operating expenses 7,452   3,894  Operating loss(7,452)  (3,894) Other income 17   67  Net loss(7,435) (3,827) Accretion of redeemable convertible preferred stock to redemption value(95,016)  —  Net loss attributable to common stockholders$(102,451) $(3,827) Net loss per share attributable to common stockholders, basic and diluted$(83.36) $(4.58) Weighted-average common shares outstanding, basic and diluted 1,229   836   Werewolf Therapeutics, Inc.Condensed Consolidated Statements of Operations (unaudited)(amounts in thousands, except per share data)

The News Highlights

  • Werewolf Therapeutics Reports First Quarter 2021 Finances
  • Check the latest News news updates and information about business, finance and more.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
How to secure your hybrid working, tips by Microsoft

For Android, the Microsoft Edge Beta Channel is now available

You can install different Edge Insider channels side-by-side on your Android phone or tablet, just as you would on your desktop. Both the Canary and Dev ...
The £48m chasm the Rangers reclaimed from Celtic as the finance expert points to the next crucial moment

The £48m chasm the Rangers reclaimed from Celtic as the finance expert points to the next crucial moment

He told Football Insider: “The revenue gap was £59m between the two and now it’s decreased to £11m. That was without Rangers playing in the Champions League. ...
Support for GTA Online, Max Payne 3, and L.A. Noire on Xbox 360 will be phased off this year

Support for GTA Online, Max Payne 3, and L.A. Noire on Xbox 360 will be phased off this year

On September 16th, the sale of GTA Online’s in-game Shark Cards items will be discontinued and online support and website stat tracking for Max Payne 3 and ...
Pilgrim's Pride buys Kerry Consumer Foods Meat and Meal Business - Greeley Tribune

Pilgrim’s Pride buys Kerry Consumer Foods Meat and Meal News – Greeley Tribune

The sale is expected to close in the fourth quarter of 2021. Kerry Meats and Kerry Meals are among the leading meat and meat snack businesses in the U.K., ...
YouTube pulls Henderson county commissioners’ meeting regarding upload for medical misinformation

YouTube pulls Henderson county commissioners’ meeting regarding upload for medical misinformation

The online video sharing and social media platform took down the video of Wednesday’s Board of Commissioners meeting, saying the upload violated YouTube’s ...
Apple Inc. (AAPL) is up 1.2600% for the month of June

Foxconn and TSMC, two Apple iPhone suppliers, have purchased millions of COVID-19 vaccinations for Taiwan

The problem is that China sees Taiwan as part of the country rather than its own independent country. China is reportedly trying to block Taiwan’s vaccine ...
Atrium Health Cabarrus and Keselowski Team Up for Veterans Program |  local news

Atrium Health Cabarrus and Keselowski Team Up for Veterans Program | local news

Source “At its core, the Checkered Flag Foundation is about giving back to those that have served our great nation and protected its freedoms. Being able to ...
What PS Plus Games Would You Like for Free in July 2021?

What PS Plus Games Would You Like for Free in July 2021?

When Will July 2021’s Free PS Plus Games Be Announced? PlayStation Plus games are routinely announced on the last Wednesday of the month, which means we’ll ...
YouTube tests Automatic Translation of Titles For Better Streaming

YouTube now has official Picture-in-Picture compatibility for iOS, which is rolling out internationally

Picture-in-Picture (PiP) allows users to watch YouTube videos in a small mini player while simultaneously browsing outside of the YouTube app on their mobile ...
Roseburg Man Suspected Going In After Alleged Street Race Accident |  News

Roseburg Man Suspected Going In After Alleged Street Race Accident | News

The investigation is ongoing, and the Toyota was towed from the scene. The 2017 blue Toyota 86 crashed into Denny’s Satellite Shop at 172 NE Exchange ...
Show next
Compsmag - Latest News from tech, business and health
Logo